Revenue, 2025

USD 1.5 Billion

Forecast, 2035

USD 2.9 Billion

CAGR, 2026-2035

6.8%

Report Coverage

Middle East

Middle East Oncology Diagnostics Market  Trends For 2026

The Middle East oncology diagnostics market size was estimated at USD 1.5 billion in 2025 and is predicted to increase from USD 1.6 billion in 2026 to approximately USD 2.9 billion by 2035, expanding at a CAGR of 6.8% from 2026 to 2035. Analysis also highlights that the Middle East oncology diagnostics market is rapidly expanding due to the increasing incidence of various cancer cases, growing early disease detection, rising demand for minimally invasive testing solutions, increasing advancements in liquid biopsy-based detection, expansion of genomic testing services, increasing interest in molecular diagnostics, and growing collaborations.

Key Takeaways

• Middle East oncology diagnostics industry poise to reach USD 1.6 billion by 2026.
• Forecasted to grow to USD 2.9 billion by 2035.
• Expected to maintain a CAGR of 6.8% from 2026 to 2035.
• By product type, the consumables segment held a dominant revenue share of 58% of the market in 2025.
• By product type, the genomic testing services subsegment held 2.50% of market share in 2025 and is expected to grow at the fastest CAGR of 8.2% during the forecast period.
• By technology type, the in vitro diagnostics segment held a dominant revenue share of 31% of the market in 2025.
• By technology type, the liquid biopsy subsegment held 2% of market share in 2025 and is expected to grow at the fastest CAGR of 10% during the forecast period.
• By cancer type, the breast cancer segment held a dominant revenue share of 22% of the market in 2025.
• By cancer type, the blood cancers segment held 11% of market share in 2025 and is expected to grow at the fastest CAGR of 8% during the forecast period.
• By clinical positioning type, the screening segment held a dominant revenue share of 25% of the market in 2025.
• By clinical positioning type, the liquid biopsy-based detection subsegment held 3% of market share in 2025 and is expected to grow at the fastest CAGR of 11% during the forecast period.
• By end user, the hospitals & cancer centers segment held a dominant revenue share of 57% of the market in 2025.
• By end user, the genomic testing laboratories subsegment held 3% of market share in 2025 and is expected to grow at the fastest CAGR of 9.5% during the forecast period.

Market Overview 

Middle East oncology diagnostics refers to tests and methods used for the detection and monitoring of different types of cancers across the Middle East. They include a wide range of laboratory tests, biopsies, molecular tests, and imaging studies. These tests help in early cancer detection, monitoring their progression, accurate diagnosis, and treatment guidance.

Moreover, the Middle East oncology diagnostics market accounted for USD 1.50 billion in 2025 and is anticipated to rise at a 6.8% CAGR during the forecast period, which is driven by rising cancer incidence, healthcare investment, expansion of oncology infrastructure, molecular testing, advanced imaging, precision-medicine adoption, and increasing demand for earlier and more precise cancer diagnosis. The market is also shifting beyond conventional pathology and imaging toward genomic profiling, ctDNA monitoring, liquid biopsy, digital pathology, companion diagnostics, and AI-assisted diagnostic workflows.

Analyst View - Market Size

The rise in the transition from diagnosis based primarily on tissue pathology and conventional imaging toward multi-modal cancer diagnostics that combine pathology, molecular testing, genomic profiling, and advanced imaging is driving the market growth. Additionally, compared with several mature diagnostic categories, molecular diagnostics, liquid biopsy, and companion diagnostics have higher growth potential because they support treatment selection, recurrence detection, and response monitoring.

Segmental Insights

Consumables Segment Dominates the Market with 58% share in 2025

As per our senior research analyst, Payal Rabde, the table covers different types of products along with their market share, CAGR, and growth drivers. The consumables segment held the largest share of 58% of the market in 2025, due to growth in cancer testing volumes, a rise in precision-oncology workflows that fueled the demand for biomarker kits and antibodies, and automated laboratories that increased throughput and repeat consumable utilization. The genomic testing services subsegment held 2.50% market share in 2025 and is expected to show the highest growth at 8.20% CAGR during the forecast period, due to increasing precision oncology driving demand for comprehensive genomic profiling, pharmacogenomic and biomarker testing expanding clinical applications, and reference laboratories enabling access without local NGS infrastructure.

Analyst View - Product

The dominance of the consumables segment with 58% market share highlights that every diagnostic workflow consumes reagents, antibodies, kits, and probes, contributing to the recurring nature of oncology testing. Similarly, the rise in PCR, NGS, and multiplex testing is propelling kits & reagents, making them the fastest-growing major consumable category at 7.6% CAGR.

Furthermore, compared to pathology and imaging instruments in the instruments segment, molecular diagnostic instruments are experiencing faster growth, leading to expansion of precision oncology. While a smaller share contributes to the services segment, creating an important outsourcing opportunity, especially for genomic testing and digital pathology.

In Vitro Diagnostics Segment Leads the Market with 31%

The given table suggests that the in vitro diagnostics segment dominated the market with 31% in 2025, as IVD supported routine biomarker and pathology testing across cancer centers, higher diagnostic volumes sustained demand for laboratory-based assays, and automation improved throughput and standardization. The liquid biopsy subsegment held 2% market share in 2025 and is anticipated to expand rapidly at a 10% CAGR during the predicted period, as blood-based testing reduces dependence on invasive sampling, ctDNA enables repeated molecular monitoring, and precision-oncology programs accelerate clinical adoption.

Analyst View - Technology

The market encompasses a relatively balanced technology structure with 31% contributing to IVDs, 30% to molecular diagnostics, and 25% to imaging categories, which makes growth differential more important than the current share. The molecular diagnostics, NGS, and ctDNA/cell-free DNA growing at a CAGR of 8.1%, 9.2%, and 10.1%, respectively, reflects that the technology mix is gradually shifting toward diagnostics offering genomic and molecular information along with conventional pathology.

Breast Cancer Segment Held a Dominant Share of 22% of the Market

Based on our research, the data covers various types of cancers, their market share in 2025, and CAGR. The breast cancer segment held the major market share of 22% in 2025, due to high testing demand supported by imaging and biomarker diagnostics, screening and early-detection programs, which expanded diagnostic volumes, and growth in HER2 and hormone-receptor testing. The blood cancers segment held 11% market share in 2025 and is expected to show the fastest growth at 8% CAGR during the upcoming years, due to increasing demand for flow cytometry for detailed hematological diagnosis, growing use of molecular profiling to guide targeted treatment, and a shift towards specialized oncology centers for advanced hematology testing.

Analyst View - Cancer Type

The importance of screening, imaging, pathology, and HER2/hormone-receptor testing is increasing as the breast cancer segment held the major share of the market in 2025, while the expansion of the lung cancer segment at 16% market share contributes to the growing importance of CT/PET and molecular profiling. Whereas the highest growth is anticipated in the blood cancer segment, which is supported by flow cytometry, immunophenotyping, molecular profiling, and specialized hematology testing, making it the most relevant segment for advanced diagnostic laboratories.

Screening Segment Contributed to 25% of Market Share

As per the analysis, the screening segment registered dominance over the market with a 25% share in 2025, due to national cancer-control programs which increased screening activity, breast and cervical screening created recurring diagnostic demand, and increased awareness campaigns encouraged earlier participation in testing. The liquid biopsy-based detection subsegment held 3% market share in 2025 and is expected to show the highest growth at 11% CAGR during the forecast period, due to blood-based assays providing minimally invasive testing, ctDNA platforms supporting emerging early-detection applications, and biopharma partnerships accelerating clinical validation.

Analyst View - Clinical Positioning

The largest clinical position is held by the screening segment with a 25% market share, which demonstrated slow growth compared to early detection, growing at an 8.0% CAGR. The highest growth areas are molecular and liquid-biopsy applications, where the potential of minimally invasive molecular testing is highlighted by liquid-biopsy-based early detection expanding at an 11.0% CAGR, while their clinical validation, regulatory acceptance, reimbursement, and integration into screening pathways also remain important adoption considerations.

Hospitals & Cancer Centers Segment Held Major Revenue Share of 57%

According to the survey conducted, the table focuses on various end users along with their market shares and CAGR. The hospitals & cancer centers segment led the market with a 57% share in 2025, due to high volumes of cancer diagnosis and staging, new oncology centers that expanded access to advanced diagnostics, and integrated care pathways, which encouraged in-house testing. The genomic testing laboratories subsegment held a 3% market share in 2025 and is expected to expand rapidly with a 9.5% CAGR during the forecast period, as precision oncology drives comprehensive genomic profiling, pharma partnerships expand biomarker testing volumes, and advanced sequencing infrastructure supports complex assays.

Analyst View - End User

The hospitals & cancer centers segment contributed to the principal demand base, with 57% market share in 2025, which was backed by high cancer-testing volumes, enhanced access to imaging and pathology infrastructure, and integrated oncology pathways. The rapid expansion of the diagnostic laboratories segment at 7.7% CAGR accounted for the fastest-growing major end-user group, where the genomic testing laboratories segment, growing at 9.5% CAGR, mirrors the increasing requirement for specialized infrastructure and expertise for NGS and advanced molecular testing.

TAM, SAM, SOM, Consumer Behavior & Buyer Intelligence Analysis

Based on the information gathered by our senior researcher, Aman Singh, the table encompasses TAM dimensions with real data and market interpretation. It highlights that the total oncology diagnostics opportunity is driven by pathology, imaging, and other diagnostic services, while liquid biopsy promotes high-growth molecular opportunities. Cancer diagnostic demand pool fuels cancer screening, testing, and monitoring, whereas precision oncology TAM expands genomic profiling and biomarker testing opportunities.

Analyst View - TAM

The broadest opportunity extends beyond conventional diagnostic testing into precision oncology infrastructure. One of the clearest high-growth niches is provided by liquid biopsy and offers a substantially faster growth trajectory than the overall oncology diagnostics market, as per the supplied Towards Healthcare benchmark. 

SAM Analysis

The above-mentioned table represents that 57% of hospitals and cancer centers held the largest serviceable institutional buyer pool; diagnostic laboratories, with 25%, are expanding the platform for specialized testing, while molecular diagnostics, with 30%, drives major opportunities across PCR, NGS, and liquid biopsy. The rapid expansion of genomic testing laboratories with 9.5% CAGR offers advanced infrastructure; liquid biopsy holds a specialized position within molecular oncology diagnostics, whereas precision oncology diagnostics supports biomarker, genomic, and companion-diagnostic services.

Analyst View - SAM

The organizations with laboratory infrastructure, specialist personnel, validated testing workflows, and oncology referral volumes are the key areas for the serviceable market. It is confirmed that molecular/genomic testing is the most technically demanding portion of the SAM, suggesting that providers may invest in either local infrastructure or outsource complex testing to reference laboratories.

SOM Analysis

As per our research, SOM should not be calculated as an arbitrary percentage of the USD 1.50 billion market for oncology diagnostics. Thus, the obtainable revenue is based on the addressable buyer network, installed infrastructure, reimbursement environment, and test volumes.

Analyst View - SOM

According to the above-mentioned data, the most realistic obtainable market is concentrated in high-volume hospitals, specialized cancer centers, reference laboratories, and genomic-testing laboratories. The number of qualified accounts, contracted testing volumes, the breadth of the diagnostic menu, installed instruments, reimbursement/access, and physician referrals are the primary factors for the determination of SOM for vendors.

Consumer Behavior Analysis

As per our senior research analyst, Payal Rabde, the table covers factors influencing consumer behavior, along with their implication on the market. Minimally invasive testing contributes to the highest consumer preference due to its convenience and lower invasiveness. On the other hand, early detection is expanding rapidly due to growing cancer screening initiatives.

Analyst View - Consumer Behavior

Patient behavior is driven by diagnostics that offer earlier information, greater personalization, and lower procedural burden, where these preferences align particularly with blood-based liquid biopsy. Nevertheless, physician recommendation, reimbursement, clinical validation, and affordability are also essential for determining their adoption rather than consumer acceptance alone.

Buyer Intelligence Analysis

Based on the information gathered, a wide range of technology selection criteria such as clinical accuracy and validation, turnaround time, cost per test, test-menu breadth, instrument throughput, reagent availability, laboratory automation, compatibility with existing infrastructure, specialist availability, data interpretation and bioinformatics, regulatory/accreditation requirements, reimbursement and economic value, vendor technical support, and scalability for future genomic testing are responsible for boosting purchasing priorities among the buyer groups.

Analyst View - Buyer Intelligence

Complete diagnostic workflows are being increasingly purchased by institutional buyers instead of standalone instruments. Moreover, considering a molecular-testing platform, requiring instruments, assay validation, reagents, interpretation, technical support, and bioinformatics, creates opportunities for vendors providing integrated solutions as well as for reference laboratories offering advanced testing, eliminating the need for every hospital to build its own NGS or liquid-biopsy infrastructure.

Key Commercial Opportunity Areas

According to our research, the table highlights various market opportunities along with their market shares and CAGR. Therefore, the expansion of diagnostics, laboratories, services, specialized centres, and various cancer types is creating new openings for innovations, collaborations, and investments, which is anticipated to fuel market growth.

Company Intelligence - Middle East Oncology Diagnostics Market

As per the analysis, different types of companies, their oncology diagnostic exposures, products, Middle East significance, and strategic goals are covered in this table. Roche, Thermo Fisher, Siemens Healthineers, and Danaher are the major market players, while Abbott, QIAGEN, Illumina, Agilent, BD, Hologic, Bio-Rad, Sysmex, GE HealthCare, Philips, Fujifilm, and others are relevant participants across Middle East cancer diagnostics, molecular diagnostics, biopsy, and imaging.

Roche Diagnostics - Regional Company Intelligence

• Roche combines oncology therapeutics and diagnostics, which help in expanding its exposure across the cancer-care pathway.
• The company has operated a dedicated regional management center since 2012 across the Middle East, where its regional operations offer IVD, services, and digital solutions to healthcare providers.
• For its division, Roche's Middle East business has headquarters in the UAE and regional centers in Saudi Arabia.
• Its oncology diagnostics portfolio consists of immunohistochemistry, in-situ hybridization, molecular diagnostics, companion diagnostics, digital pathology, and tumor profiling.
• Its Foundation Medicine portfolio includes FoundationOne CDx, FoundationOne Liquid CDx, and FoundationOne Heme, with tests analyzing more than 300 cancer-related genes through NGS-based comprehensive genomic profiling.

Analyst View:

Rather than competing in only one diagnostic modality, the ability of connecting pathology, biomarker testing, molecular diagnostics, and treatment-selection workflows contributes to Roche's strategic relevance.

Thermo Fisher Scientific – Oncology & Genomics

• Thermo Fisher is relevant to the NGS and precision-oncology portion of the market.
• Its oncology-related portfolio consists of Ion Torrent sequencing, Oncomine precision-oncology assays, molecular testing, NGS workflows, sample preparation, bioinformatics, and companion-diagnostic applications.
• Based on a 2025 Middle East cancer-diagnostics analysis, Thermo Fisher is recognized among the key regional participants.
• To expand localized access to NGS-based cancer testing across more than 30 countries, including Middle Eastern markets, Thermo Fisher announced a collaboration with Pfizer.

Analyst View:

Thermo Fisher accounts for the market's 9.2% NGS CAGR and broader 8.1% molecular diagnostics growth opportunity across the market.

Siemens Healthineers - Imaging & Diagnostic Infrastructure

• Siemens Healthineers offers CT, MRI, PET/CT, molecular imaging, advanced imaging workflows, and laboratory diagnostics, making it substantially relevant to the imaging diagnostics segment.
• Furthermore, a CT scanner using its photon-counting technology and AI capabilities was presented at Arab Health by the company in January 2025.

Analyst View:

In oncology diagnostics, Siemens is positioned across the infrastructure-heavy portion, supporting cancer centers that require high-end imaging for localization, staging, and treatment monitoring.

Danaher – Multi-Platform Diagnostics

Danaher's standing in the market is driven by its portfolio of diagnostic businesses and technologies, including molecular diagnostics, PCR, anatomic pathology, laboratory automation, cell analysis, and diagnostic workflow systems.

Additionally, based on the information gathered, the company is recognized as one of the major participants in both the global cancer-diagnostics market and the Middle East/MEA IVD landscape.

Analyst View:

The market's movement toward integrated laboratory workflows is the most relevant to Danaher's broad platform exposure instead of individual diagnostic instruments.

Company Competitive Positioning by Technology

Based on the survey conducted by our senior researcher, Aman Singh, the table illustrates relevant portfolio exposure, which is a qualitative technology-mapping indicator, not market share. It indicates that all the companies are actively focusing on digital or AI capabilities, while most of the companies are also strengthening their molecular/PCR, NGS, and genomics capabilities.

Company-Level Research Metrics

As per the information gathered, various factors are responsible for maintaining the company's position in the market. The table highlights that growth of oncology diagnostic revenue, distribution networks, installed systems, oncology product portfolio, collaborations, Middle East facilities, and strategic investments are important factors for the company to contribute to the significant market expansion.

Complete Market Segmentation Listing

By Product

• Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
  • Assay Controls & Standards
  • Other Consumables
• Instruments
  • Pathology-Based Instruments
    • Slide Staining Systems
    • Tissue Processing Systems 
    • Cell Processors
    • Digital Pathology Systems
    • Other Pathology Instruments
  • Molecular Diagnostic Instruments
    • PCR Instruments
    • NGS Instruments
    • Microarray Systems
    • Other Molecular Platforms
  • Imaging Instruments
    • CT Systems
    • MRI Systems
    • PET Systems
    • Mammography Systems
    • Ultrasound Systems
• Services
  • Diagnostic Testing Services
  • Laboratory Services
  • Genomic Testing Services
  • Digital Pathology Services
  • Data & Interpretation Services

By Technology

• In Vitro Diagnostics
  • Immunoassays
  • Histopathology
  • Immunohistochemistry
  • Flow Cytometry
  • Cytology
• Molecular Diagnostics
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • In Situ Hybridization (ISH)
  • Cell-Free DNA / ctDNA Testing
  • DNA Methylation Analysis
  • Microarrays
  • Isothermal Nucleic Acid Amplification
  • Other Molecular Technologies
• Imaging Diagnostics
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound
• Biopsy-Based Diagnostic
  • Tissue Biopsy
    • Core Needle Biopsy
    • Fine-Needle Aspiration
    • Surgical Biopsy
  • Liquid Biopsy
    • ctDNA
    • CTC Analysis
    • Cell-Free RNA
  • Image-Guided Biopsy
• Other Diagnostic Technologies
  • Endoscopy
  • Tumor Marker Testing
  • Digital Pathology
  • AI-Assisted Diagnostics

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Cervical Cancer
• Blood Cancers
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
• Skin Cancer
  • Melanoma
  • Non-Melanoma Skin Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Other Cancers

By Clinical Positioning

• Screening
  • Population-Based Screening
  • High-Risk Screening
  • Opportunistic Screening
• Early Detection
  • Biomarker-Based Detection
  • Imaging-Based Detection
  • Molecular Detection
  • Liquid Biopsy-Based Detection
• Diagnosis & Confirmation
  • Histological Diagnosis
  • Molecular Confirmation
  • Biomarker Confirmation
• Therapy Selection
  • Companion Diagnostics
  • Genomic Profiling
  • Biomarker Testing
  • HER2 / Hormone-Receptor Testing
• Treatment Response Assessment
  • Imaging-Based Monitoring
  • ctDNA Monitoring
  • Tumor Marker Monitoring
• Recurrence & Disease Monitoring
  • Minimal Residual Disease Testing
  • Molecular Recurrence Testing
  • Surveillance Imaging

By End User

• Hospitals & Cancer Centers
  • Public Hospitals
  • Private Hospitals
  • Specialized Cancer Centers
  • Academic Medical Centers
• Diagnostic Laboratories
  • Hospital-Based Laboratories
  • Independent Laboratories
  • Reference Laboratories
  • Genomic Testing Laboratories
• Research Institutes
  • Academic Research Institutes
  • Government Research Centers
  • Clinical Research Organizations
• Pharmaceutical & Biotechnology Companies
  • Companion Diagnostics Development
  • Clinical Trial Testing
  • Biomarker Research
• Other End Users
  • Ambulatory Care Centers
  • Specialty Clinics
  • Physician Practices

Strategic Market Key Takeaways

Our senior researcher, Aditi Shivarkar,  conducted a detailed research, analysing company data, clinical trends, and industry developments. Based on her comprehensive analysis, the following strategic key takeaways highlight the most important market insights and opportunities.

For Service Providers & CDMOs 

• Invest in molecular diagnostics.
• Support oncology and translational research. 
• Focus on genomic testing services.

For Pharma & Biotech Companies 

• Collaborate to expand companion diagnostics 
• Invest in biomarker identification.
• Focus on expanding genomic and molecular testing.

For Investors & Corporate Strategy Teams

• Invest in in vitro diagnostics.
• Support liquid biopsy-based detection 
• Keep track of emerging diagnostic products.

Expert Insights

Based on the assessment, the market is expanding rapidly due to increasing incidences of cancer across the Middle East. The growth in health awareness and government initiatives are also promoting their early detection. The new collaborations among the major companies can accelerate the development of new diagnostic products and enhance access to their services. Strong growth in molecular diagnostics and genomics are also expected to create new market opportunities.

Our Experts

Payal Rabde, Senior Research Analyst, led the primary market research, developed the methodology, analysed trends, segmentation, competition, forecasts, and strategic opportunities, forming the report's analytical foundation. 

Aman Singh, senior researcher, was responsible for collecting and validating clinical trial data, research publications, company information, partnerships, and other quantitative datasets, strengthening evidence-based analysis and market estimations. 

Aditi Shivarkar, senior researcher, reviewed the complete research document, performed quality checks, validated findings, refined content, corrected inconsistencies, and finalized the report, ensuring accuracy, clarity, credibility, and publication-ready quality.